Event preview: BIO-Europe returns to Hamburg
Supported by regional hosts, the northern Germany biomedical cluster organisation Life Science Nord, the City of Hamburg, and the State of Schleswig-Holstein, BIO-Europe 2019 is expected to bring together 4,400 executives from more than 2,300 life sciences companies from more than 60 countries.
Delegates will engage in both one-to-one partnering and a programme that includes 140 company presentations and more than 130 exhibitors.
Partnering is now open, powered by EBD’s platform, partneringONE. The newly-enhanced partneringONE provides opportunities to find and negotiate asset deals and strategic collaborations.
“We are pleased to be hosted by one of Europe’s most important locations for life sciences.” - Anna Chrisman, EBD Group.
This year’s BIO-Europe is expected to exceed 2018’s number of 26,000 one-to-one meetings around drug discovery partnerships, with 5,200 licensing opportunities on offer.
“We are excited that Hamburg has been chosen to host BIO-Europe for the third time,” said Hinrich Habeck, managing director of Life Science Nord.
“Hamburg is all about connecting, having more bridges than any other place in Europe. In line with this great tradition, Life Science Nord builds bridges to connect its 500 companies, research facilities and institutions to create a truly innovative and hands-on community.”
The programme includes 25 panels with industry experts speaking on investment and business development, therapeutic areas such as immuno-oncology, gene therapy, digital medicine, the microbiome, and women’s health, as well as a special plenary on the last 25 years in biotech and a ‘Startup Slam’ pitch competition sponsored by Johnson & Johnson.
“We are pleased to be hosted by one of Europe’s most important locations for life sciences, the Life Science Nord Cluster of Hamburg and Schleswig-Holstein,” said Anna Chrisman, group managing director, EBD Group.
“This life sciences cluster employs more than 49,000 people in the biotech, pharma and medtech fields, with internationally renowned research institutes and universities producing ground-breaking research in unmet medical needs, making it the perfect setting for the discovery and dealmaking that takes place at BIO-Europe to further global drug development.”
A new report by EBD Group and Pharma Intelligence, “ Pharma Partnering Trends Revealed: 2019 Edition”, describes the types of partnering deals that have been most successful in recent years. Download it for inside information that can be applied in one-to-one meetings at BIO-Europe.
To register and for more information on the event, click here .
About EBD Group
EBD Group’s overriding mission is to help collaborations get started across the life sciences value chain. Its range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Its landmark events held in key life sciences markets around the world are powered by partneringONE.
EBD’s events (BIO-Europe, BIO-Europe Spring, BioPharm America, Biotech Showcase, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio Partnering Forum, Rare Disease Innovation and Partnering Summit, Cell & Gene Meeting on the Med, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings.
